Drugs / Bone Marrow Aspirate

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02319720 Jul 2008 → Mar 2013 ulcer disease Dr. E.Badiavas Terminated No outcome recorded
Phase 21 trial
Phase 2 NCT02709343 Apr 2017 → Sep 2023 chronic transplant rejection The University of Queensland Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT05517434 Jan 2025 → Jun 2026 overdue osteoarthritis, knee University Health Network, Toronto Recruiting No outcome recorded
Phase 32 trials
Phase 3 NCT06238934 Mar 2024 → Mar 2025 overdue osteoarthritis, knee National Institute of Traumatology and Orthopaedics Not yet recruiting No outcome recorded
Phase 3 NCT03818737 Mar 2019 → May 2022 osteoarthritis Emory University Completed No outcome recorded
Phase not applicable2 trials
NCT06893302 Jun 2026 → Apr 2028 expected osteoarthritis, knee Hospital for Special Surgery, New York Recruiting No outcome recorded
NCT07242729 Feb 2025 → Feb 2027 expected plantar fasciitis Federal University of São Paulo Recruiting No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT05507099 Comparator Aug 2022 → Aug 2028 expected osteoarthritis Grigory Karmy Recruiting No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT03580148 Comparator Oct 2015 → Jul 2020 osteoarthritis Women's College Hospital Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as Bone Marrow Aspirate ClinicalTrials.gov intervention name — accepted as the source's own label NCT05507099
6

NCT02319720

NCT05517434

NCT06238934

NCT07242729

NCT03580148

NCT06893302

Known as BMA “Bone Marrow Aspirate (BMA): Minimally manipulated autologous cellular preparation” NCT05517434
1

“Biological: Bone Marrow Aspirate (BMA)” NCT06893302

Known as Bone Marrow Derived MSCs ClinicalTrials.gov intervention name — accepted as the source's own label NCT03818737
1

NCT02709343

Modality Cell therapy “Allogeneic ex vivo expanded, bone marrow-derived mesenchymal stromal cells” NCT02709343
Route Other “Fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken.” NCT02319720